Kinetics of Serum β-D-glucan During Peritonitis With Candida in Resuscitation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-01

Study Completion Date

2023-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Intraabdominal fungal infections with Candida are constantly increasing. Their diagnosis and treatment is difficult. Morbidity and mortality are high. Β-D-Glucan has been proposed as a marker of systemic fungal infection in candidemia. Moreover, its kinetics is associated with therapeutic success. On the other hand, there are no data on intraabdominal infections that are much more frequent. The objective of the study is to evaluate the initial levels of β-D-glucan and its daily kinetics during the treatment of fungal peritonitis in resuscitation compared to a control group with a yeast-free peritonitis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of BD Glucan in Peritoneal Fluid for the Diagnosis of Fungal Peritonitis

NCT03469401

Adult Patient (Over 18 Yr-old) Admitted to the ICU for Acute Peritonitis

COMPLETED

Diagnostic Performance of the CandID PLUS PCR for the Diagnosis of Intra-abdominal Candidiasis in Critically Ill Patients

NCT07005258

Intra-Abdominal Infection Candida Peritonitis Infectious +2 more

COMPLETED

Dosage of Plasma 1, 3-β-D-glucan for the Diagnosis of Candidemia.

NCT03674359

Infection, Fungal

UNKNOWN

A B-D-Glucan Driven Antifungal Stewardship Approach for Invasive Candidiasis

NCT03090334

Invasive Candidiases Abdominal Infection

TERMINATED NA

β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients

NCT00672841

Invasive Candidiasis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peritonitis Infectious Candida Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with fungal peritonitis

Group Type OTHER

To evaluate the initial levels and kinetics of serum β-D-glucan

Intervention Type OTHER

To evaluate the initial levels and kinetics of serum β-D-glucan during fungal peritonitis compared to a control group of yeast-free peritonitis

Patients with peritonitis without yeast

Group Type OTHER

To evaluate the initial levels and kinetics of serum β-D-glucan

Intervention Type OTHER

To evaluate the initial levels and kinetics of serum β-D-glucan during fungal peritonitis compared to a control group of yeast-free peritonitis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

To evaluate the initial levels and kinetics of serum β-D-glucan

To evaluate the initial levels and kinetics of serum β-D-glucan during fungal peritonitis compared to a control group of yeast-free peritonitis

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Major Patient (age ≥ 18 years)
* Community or associated peritonitis, operated and hospitalized in resuscitation
* Affiliation to a social security scheme

Exclusion Criteria

* Allergy known to echinocandins
* Dying Patient
* Limitation of care
* Predictable duration of follow-up ≤ 10 days
* Transfusion within 3 months
* Patient minor, patient under guardianship or curatorship

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No